Nephros, Inc. — FY 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017; filed February 26, 2018. The filing reports annual results, not standalone fourth-quarter results. Nephros develops and sells water ultrafiltration products and hemodiafiltration (HDF) systems. Its near-term commercial focus is water filtration; it is also developing a second-generation HDF system.
Financial results and liquidity
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $3.809 million | $2.320 million |
| Gross profit / gross margin | $2.292 million / 60% | $1.294 million / 56% |
| Operating expenses | $4.518 million | $4.163 million |
| Operating loss | $2.226 million | $2.869 million |
| Net loss | $0.809 million | $3.032 million |
| Cash used in operating activities | $0.077 million | $2.112 million |
| Cash at year-end | $2.194 million | $0.275 million |
| Working capital | $1.938 million | $0.369 million |
Revenue increased 64%, primarily on higher filter sales. Gross margin rose four percentage points, which management attributed to pricing, sales-channel and distributor mix, and foreign exchange. SG&A increased 15% to $3.298 million, while R&D declined 7% to $1.002 million. Interest expense rose to $302,000 from $172,000.
The reported 2017 net loss included a $1.789 million income tax benefit from selling New Jersey tax-credit and net-operating-loss carryforwards; this materially reduced the reported loss and is not an operating profit. The company reported a $2.598 million pretax loss. No dividends were paid or anticipated.
At year-end, current assets were $3.809 million and current liabilities were $1.871 million. Debt included $711,000 outstanding on a secured revolving facility and an unsecured note with a $954,000 net carrying value; the notes bear 11% interest and principal is due June 2019. The revolver has a $1 million limit, with approximately $289,000 available at year-end, and is secured by company assets.
Business developments and material changes
- Nephros began shipping HydraGuard hospital filters and EndoPur dialysis filters in 2017; it also launched a lead-filtration system late in the year. These products were at early stages of commercialization.
- Management cited the 64% revenue increase as early evidence of progress in hospital water-infection-control filtration. Four customers generated 50% of annual revenue, versus 55% in 2016.
- The company continued development of a second-generation HDF system, informed by post-market evaluations; the last evaluation concluded at Vanderbilt in early 2018. Development is intended to improve manufacturability, treatment cost, and clinic workflow, and is to be funded as cash flow permits.
- Medica agreement amendments expanded covered products and extended the agreement through 2025. The agreement entails approximately $30.3 million of minimum purchase commitments over its remaining term, including $2.7 million due within one year.
- Common shares outstanding increased from 49.8 million at year-end 2016 to 55.3 million at year-end 2017, reflecting equity financing and other issuances. Warrants and options create additional potential dilution.
Outlook, risks, and unusual items
Management expected existing cash and projected product-sales growth to fund operations through 2018, but cautioned that the company may need additional financing. The auditor’s report includes a going-concern explanatory paragraph: recurring losses and insufficient operating cash flow raise substantial doubt about the company’s ability to continue as a going concern within one year after issuance. Management’s plans depend on revenue growth, higher gross profit, and improved operating cash flow; there is no assurance these will be achieved. The statements contain no going-concern adjustments.
- Profitability and funding: Nephros had an accumulated deficit of $121.1 million and reported operating losses in every quarter since inception. Failure to raise capital or generate cash could force cuts or cessation of operations.
- Commitments and supplier exposure: The Medica minimum-purchase obligations are substantial relative to current revenue and liquidity. Nephros relies on third-party manufacturers and suppliers and has agreed to pay 12% interest on certain overdue Medica invoices.
- Commercial and customer risks: Adoption, pricing, distribution, reimbursement, and ability to scale production remain uncertain; revenue and receivables are concentrated among a small number of customers.
- Regulatory and product risks: Medical-device compliance, approvals, quality control, product liability, and product performance could affect sales or result in enforcement, recalls, or claims. Product-liability insurance is $2 million.
- Capital markets and dilution: The stock trades on the OTCQB with limited trading and significant price volatility. Additional share, warrant, or option issuance could dilute investors; Lambda beneficially owned approximately 54% of shares as of February 2018.
- Tax and accounting: The 2017 tax benefit arose from a New Jersey tax-credit/NOL sale. The company was still assessing certain effects of the Tax Cuts and Jobs Act; it expected to accelerate $278,000 of Bellco deferred revenue into opening retained earnings upon adopting the new revenue standard in 2018.
The company reported no pending legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2017. The independent auditor gave an unqualified opinion on the financial statements, alongside the going-concern uncertainty.
Investor verification priorities
- Track quarterly cash use, sales growth, gross margin, and whether management’s stated 2018 funding runway was achieved.
- Review the terms, borrowing-base availability, covenants, and repayment or renewal status of the secured revolver and the June 2019 unsecured notes.
- Assess whether product sales and demand can support the Medica minimum-purchase commitments, and confirm payments, overdue balances, and any applicable 12% interest.
- Verify commercial traction and regulatory status for HydraGuard, EndoPur, the lead-filtration system, and the second-generation HDF program.
- Monitor customer concentration, receivable collections, additional financing needs, and potential dilution from shares, options, and warrants.
- Confirm the accounting and tax effects of the Bellco revenue-standard transition and the Tax Act, including any subsequent revisions to estimates.